Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)

Arthritis Rheum. 2001 Jul;44(7):1717-8. doi: 10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO;2-C.
No abstract available

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / immunology
  • Humans
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / immunology
  • Rituximab
  • Rodentia
  • Serum Sickness / etiology*
  • Serum Sickness / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Recombinant Fusion Proteins
  • Rituximab